Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients
出版年份 2019 全文链接
标题
Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients
作者
关键词
Anti-PD-1 therapy, Nivolumab, Pembrolizumab, NSCLC, Renal cell carcinoma, TIM-3
出版物
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-09-12
DOI
10.1007/s00262-019-02391-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Classification of 1-methylcyclopropene treated apples by fluorescence fingerprint using partial least squares discriminant analysis with stepwise selectivity ratio variable selection method
- (2018) Vipavee Trivittayasil et al. CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS
- Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors
- (2018) Malaka Ameratunga et al. EUROPEAN JOURNAL OF CANCER
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
- (2018) Priyanka B. Subrahmanyam et al. Journal for ImmunoTherapy of Cancer
- Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients
- (2018) Ryo Kato et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer
- (2018) Nataly Manjarrez-Orduño et al. Frontiers in Immunology
- PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
- (2017) Enrico Munari et al. Oncotarget
- mixOmics: An R package for ‘omics feature selection and multiple data integration
- (2017) Florian Rohart et al. PLoS Computational Biology
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
- (2015) D. S. Thommen et al. Cancer Immunology Research
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
- (2015) M. Callea et al. Cancer Immunology Research
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
- (2014) L.B. Jilaveanu et al. Journal of Cancer
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started